Advanced Gene Editing Technology for Therapeutic Applications
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.
Enhancing Immunogenicity and Protection in Calves
The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.
A Broadly Protective Human Antibody for GI Genogroup Noroviruses
Norovirus is a leading cause of vomiting, diarrhea, and foodborne illness worldwide, with 700 million cases and 200,000 deaths occurring each year. Despite decades of work in the field, there are no preventive or therapeutic strategies specifically approved for even the most prevalent forms of human norovirus (i.e., GI, GII genogroups), which are highly contagious and carry an increased risk of severe complications in children, older adults, and those with immunocompromising conditions.
Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections
The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.
Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia
Summary:
The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.
Compositions and Methods for Reducing Serum Triglycerides
This technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown to induce the autoantibody against the target and to lower plasma triglycerides.